Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the target of some unusual options trading activity on Wednesday. Investors bought 4,063 put options on the company. This is an increase of approximately 2,362% compared to the typical volume of 165 put options.
Xenon Pharmaceuticals Price Performance
Shares of NASDAQ:XENE traded down $1.19 during midday trading on Thursday, reaching $39.55. The company's stock had a trading volume of 190,406 shares, compared to its average volume of 349,141. The business's fifty day simple moving average is $41.04 and its 200-day simple moving average is $40.64. Xenon Pharmaceuticals has a fifty-two week low of $35.53 and a fifty-two week high of $50.99. The company has a market capitalization of $3.02 billion, a P/E ratio of -14.02 and a beta of 1.20.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same quarter last year, the firm posted ($0.73) earnings per share. On average, analysts forecast that Xenon Pharmaceuticals will post -3.1 earnings per share for the current fiscal year.
Insider Activity
In other Xenon Pharmaceuticals news, CFO Sherry Aulin sold 18,709 shares of the business's stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total value of $770,997.89. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Gary Patou sold 4,891 shares of the firm's stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $41.08, for a total transaction of $200,922.28. Following the transaction, the director now directly owns 23,573 shares of the company's stock, valued at $968,378.84. The trade was a 17.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.52% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. FMR LLC boosted its stake in shares of Xenon Pharmaceuticals by 2.2% in the 3rd quarter. FMR LLC now owns 6,917,684 shares of the biopharmaceutical company's stock valued at $272,349,000 after purchasing an additional 149,511 shares during the last quarter. Driehaus Capital Management LLC lifted its holdings in Xenon Pharmaceuticals by 2.3% in the second quarter. Driehaus Capital Management LLC now owns 4,419,472 shares of the biopharmaceutical company's stock valued at $172,315,000 after buying an additional 97,732 shares during the period. Wellington Management Group LLP boosted its stake in Xenon Pharmaceuticals by 0.4% in the third quarter. Wellington Management Group LLP now owns 3,843,447 shares of the biopharmaceutical company's stock valued at $151,317,000 after acquiring an additional 15,226 shares during the last quarter. Braidwell LP grew its holdings in Xenon Pharmaceuticals by 5.7% during the 3rd quarter. Braidwell LP now owns 2,707,255 shares of the biopharmaceutical company's stock worth $106,585,000 after acquiring an additional 146,682 shares during the period. Finally, Janus Henderson Group PLC raised its position in shares of Xenon Pharmaceuticals by 144.2% during the 3rd quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company's stock valued at $100,506,000 after acquiring an additional 1,507,135 shares during the last quarter. Institutional investors own 95.45% of the company's stock.
Analysts Set New Price Targets
XENE has been the subject of a number of recent research reports. HC Wainwright reissued a "buy" rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a report on Thursday, December 12th. Needham & Company LLC reiterated a "buy" rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Finally, Raymond James restated an "outperform" rating and issued a $50.00 target price on shares of Xenon Pharmaceuticals in a research note on Thursday, October 10th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $56.00.
Read Our Latest Research Report on XENE
Xenon Pharmaceuticals Company Profile
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Further Reading
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
